Industry Briefs: June 18, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: June 18, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Amgen has completed its acquisition of the Turkish company, Mustafa Nevzat Pharmaceuticals. Read More

Dalton Pharma Services and Clarity Pharmaceuticals have entered into a manufacturing-services agreement under which Dalton Pharma Services will provide cGMP chemistry manufacturing, scale-up, aseptic fill–finish services, and analytical support for Clarity’s positron emission tomography-based companion diagnostics and radio-immunotherapeutics development program. Read More

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM has signed a commercial agreement for contract manufacturing services using its proprietary XD high cell-density process technology with an undisclosed pharmaceutical company. Read More

In other news, Royal DSM’s tender offer to purchase all outstanding shares of common stock of the medical-device company Kensey Nash at a price of $38.50 per share was successful. Read More

Frazier Healthcare has acquired Catalent Pharma Solutions's US commercial pharmaceutical-packaging operations, based in Philadelphia, Pennsylvania, and Woodstock, Illinois. Read More

JDRF and Novo Nordisk have established an R&D collaboration for disease-modifying immunotherapies for Type I diabetes. Read More

Merck & Co. and Ambrx have agreed to design and develop rationally optimized biologic drug conjugates based on Ambrx’s site-specific protein medicinal chemistry technology. Read More

Roche’s Genentech has entered into a CHF 400-million ($418 million) agreement with AC Immune for developing anti-Tau antibodies for treating Alzheimer’s disease. Read More

Unilife has entered into a seven-year commercial supply contract with an undisclosed pharmaceutical company for the use of its Unifill prefilled syringe. Read More

Waters has began construction on its new mass spectrometry headquarters in Wilmslow, United Kingdom. Read More

People News

AMRI has appointed Srinivas Nanduri as director of medicinal chemistry at the company’s research center in Hyderabad, India, reporting to Subramanyam Maddala, president of AMRI’s India operations. In addition, Suneel Kumar Bommisetty was named senior research associate of computational chemistry, reporting to Nanduri. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here